Background: The purpose of this study was to evaluate the effects and safety of adjuvant chemotherapy with gemcitabine plus cisplatin in kidney transplant patients with T2-4 bladder or upper urinary tract transitional cell carcinoma.

Patients and methods: Twenty kidney transplant patients with T2-4 bladder or upper urinary tract transitional cell carcinoma who underwent surgery and adjuvant chemotherapy were enrolled. They were compared with 20 matched patients who were treated with surgery alone. The chemotherapy regimen was gemcitabine 800 mg/m² on days 1, 8 and 15 and cisplatin 70 mg/m² on day 2. A single treatment cycle lasted 28 days. Due to the potential concerted reaction between the immunosuppressant regimen and the chemotherapeutic agents, drug toxicities were closely observed, and a dose reduction of the chemotherapeutic agents was planned, according to the toxicity grade.

Results: The mean overall survival time of chemotherapy group was longer than that of the surgery group. The incidences of hematological toxicities and gastrointestinal reactions were higher. Grade 1 nephrotoxicity was found in 5 patients, and no other grade of nephrotoxicity was observed. Neither serum creatinine nor blood urea nitrogen were obviously deteriorated during chemotherapy.

Conclusion: Our study data suggested that kidney transplant patients with T2-4 transitional cell carcinoma may derive an overall survival benefit from the administration of adjuvant chemotherapy with gemcitabine plus cisplatin after surgery. The drugs toxicities were acceptable, and the nephrotoxicity was mild.

CITATION INFORMATION: Wang Z, Lin J, Zhu Y, Zhang J, Xiao J, Guo Y, Tian Y. Adjuvant Chemotherapy with Gemcitabine Plus Cisplatin for Kidney Transplant Patients with Transitional Cell Carcinoma. Am J Transplant. 2017;17 (suppl 3).

« Back to 2017 American Transplant Congress